<DOC>
	<DOC>NCT01131546</DOC>
	<brief_summary>This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.</brief_summary>
	<brief_title>Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Male or female outpatients, 1875 Years Patients with mild to moderate essential hypertension (defined as mean BP of 2 visits â‰¥140mm/90mmHg, and &lt; 180mm/110mmHg) Written informed consent Patients with secondary hypertension Patients with severe hypertension Have to take other drugs that can influence blood pressure during the study Allergic to DHP calcium antagonists Evidence of congestive heart failure, unstable angina or severe arrhythmia Renal or hepatic dysfunction Women who are taking contraceptive pills or are likely to be pregnant Participate in other clinical trials within 3 months prior to this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Levamlodipine Besylate</keyword>
	<keyword>Amlodipine Maleate</keyword>
</DOC>